✦ LIBER ✦

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

✍ Scribed by J. Lundkvist; Wilking; S. Holmberg; M. Lidgren; L. Jönsson

Book ID: 118624657
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 123 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80378-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of exemestane versus

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3

✍ Jonas Lundkvist; Nils Wilking; Stig Holmberg; Linus Jönsson 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 368 KB

Cost-Effectiveness of Switching to Exeme

Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer

✍ David Thompson; Douglas C. A. Taylor; Eduardo L. Montoya; Eric P. Winer; Stephen 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Cost-effectiveness of switching to exeme

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

P178 Cost-effectiveness of switching to

P178 Cost-effectiveness of switching to exemestane (EX) after 2–3 years of adjuvant tamoxifen (T) in postmenopausal (PM) early breast cancer (EBC)

✍ C.G. Pinto; M.S. Castanho; L.S. Miguel; E. Rocha 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 44 KB

PCN15 PHARMACOECONOMIC ANALYSIS OF EXEME

PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

✍ JM Gil; A Lluch; P González; A Del Castillo; F Canorea; C Rubio-Terrés 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Cost-Effectiveness of Letrozole Versus T

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer

✍ Thomas E. Delea; Jon Karnon; Oleg Sofrygin; Simu K. Thomas; Natalie L. Papo; Vic 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 194 KB